BC Week In Review | Oct 2, 2006
Clinical News

Alista alprostadil: Phase IIb data

Data from the double-blind, placebo-controlled, U.S. Phase IIb trial in 320 women with FSAD, who have undergone hysterectomy, showed that Alista missed the primary endpoint of a significant improvement over baseline in the number of...
BC Week In Review | Dec 12, 2005
Clinical News

Alista alprostadil: Completed Phase IIb enrollment

VVUS completed enrollment of >300 patients in a double-blind, placebo-controlled, U.S. Phase IIb study. Vivus Inc. (VVUS), Mountain View, Calif.   Product: Alista alprostadil   Business: Genitourinary   Molecular target: Prostaglandin E1 (PGE1) receptor  ...
BC Week In Review | May 30, 2005
Clinical News

Muse alprostadil genitourinary data

Data from a U.S. study in 73 evaluable preoperatively sexually active patients who developed erectile dysfunction (ED) after radical prostatectomy showed that early treatment with Muse improved penile function recovery. Specifically, 39% of those who...
BC Week In Review | Apr 14, 2003
Clinical News

Topiglan: Phase I; Phase II

MCHM said the FDA released a clinical hold on compounds using the company's SEPA absorption enhancer technology, including Topiglan. As a result, MCHM will begin Phase II testing of Topiglan this year. The FDA placed...
Items per page:
1 - 4 of 4